Presentation is loading. Please wait.

Presentation is loading. Please wait.

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Published byLeony Kurnia Modified over 5 years ago

Similar presentations

Presentation on theme: "Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-"— Presentation transcript:

1 Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus- Leukemia Reaction? A Prospective Phase II Study  Yves Chalandon, Eddy Roosnek, Bernadette Mermillod, Laurent Waelchli, Claudine Helg, Bernard Chapuis  Biology of Blood and Marrow Transplantation  Volume 12, Issue 1, Pages (January 2006) DOI: /j.bbmt Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 A, Incidence of aGVHD grade I and II (○) and grade II only (•). B, Incidence of cGVHD (limited and extensive) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 OS (•) and TRM (○) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 EFS (A) and incidence of relapse (B) after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 OS after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H in patients with CML (○) and in patients with other diseases (•). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 DFS after allogeneic PBSC transplantation partially T-cell depleted in vitro with Campath-1H. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-"

Similar presentations

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Similar presentations

Ads by Google